Literature DB >> 27964904

Immediate and 12-Month Outcomes of Ischemic Versus Nonischemic Functional Mitral Regurgitation in Patients Treated With MitraClip (from the 2011 to 2012 Pilot Sentinel Registry of Percutaneous Edge-To-Edge Mitral Valve Repair of the European Society of Cardiology).

Michele Pighi1, Rodrigo Estevez-Loureiro2, Francesco Maisano3, Gian P Ussia4, Gianni Dall'Ara2, Olaf Franzen5, Cécile Laroche6, Magnus Settergren7, Reidar Winter7, Georg Nickenig8, Martine Gilard9, Carlo Di Mario2.   

Abstract

In literature, there are limited data comparing ischemic mitral regurgitation (I-MR) versus nonischemic MR regarding outcomes after percutaneous "edge-to-edge" repair. We aimed to describe the early and 12-month results after MitraClip device implantation regarding the 2 etiologies. From January 2011 to December 2012, the Transcatheter Valve Treatment Sentinel Pilot Registry included 452 patients with MR who underwent MitraClip procedure in 25 centers across Europe. The prevalent etiology was I-MR (235 patients, 52.0%). I-MR group had a significantly higher proportion of men (74.9 vs 59.9%, p <0.001) and surgical risk (logistic EuroSCORE 24.8 ± 18.2 vs 18.8 ± 16.3, p <0.001). Acute procedural success was high (96%) and similar between groups (p = 0.48). Patients with I-MR required a higher, albeit not significant, number of clips to reduce MR (p = 0.08). Inhospital mortality was low (2.0%) without significant differences between etiologies. The estimated 1-year mortality and rehospitalization rates were 15.0% and 25.8%, respectively, without significant differences between groups. Paired echocardiographic data showed a persistent improvement of MR at 1 year in both etiologies. Despite a significant overall reverse atrial remodeling after clip, there were no significant changes in left ventricular volumes. In conclusion, this large independent cohort showed that percutaneous "edge-to-edge" therapy was associated with early- and long-term improvement of MR severity and functional condition both in patients with I-MR and nonischemic MR. There were no significant differences between the 2 etiologies regarding survival and freedom from rehospitalization due to heart failure at the 1-year follow-up.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27964904     DOI: 10.1016/j.amjcard.2016.10.049

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

1.  Fourteen-Year Temporal Trends in Patients Hospitalized for Mitral Regurgitation: The Increasing Burden of Mitral Valve Prolapse in Men.

Authors:  Clémence Grave; Christophe Tribouilloy; Philippe Tuppin; Alain Weill; Amélie Gabet; Yves Juillière; Alexandre Cinaud; Valérie Olié
Journal:  J Clin Med       Date:  2022-06-08       Impact factor: 4.964

Review 2.  Mitral Valve Interventions in Structural Heart Disease.

Authors:  Matteo Saccocci; Maurizio Taramasso; Francesco Maisano
Journal:  Curr Cardiol Rep       Date:  2018-05-17       Impact factor: 2.931

Review 3.  Role of Echocardiography in Transcatheter Valvular Heart Disease Interventions.

Authors:  Omar K Khalique; Rebecca T Hahn
Journal:  Curr Cardiol Rep       Date:  2017-10-27       Impact factor: 2.931

Review 4.  Transcatheter Mitral Valve Therapy: Defining the Patient Who Will Benefit.

Authors:  Marvin H Eng; Dee Dee Wang
Journal:  Curr Cardiol Rep       Date:  2018-09-12       Impact factor: 2.931

5.  Safety and Feasibility of MitraClip Implantation in Patients with Acute Mitral Regurgitation after Recent Myocardial Infarction and Severe Left Ventricle Dysfunction.

Authors:  Dan Haberman; Rodrigo Estévez-Loureiro; Tomas Benito-Gonzalez; Paolo Denti; Dabit Arzamendi; Marianna Adamo; Xavier Freixa; Luis Nombela-Franco; Pedro Villablanca; Lian Krivoshei; Neil Fam; Konstantinos Spargias; Andrew Czarnecki; Isaac Pascual; Fabien Praz; Doron Sudarsky; Arthur Kerner; Vlasis Ninios; Marco Gennari; Ronen Beeri; Leor Perl; Haim Danenberg; Lion Poles; Sara Shimoni; Sorel Goland; Berenice Caneiro-Queija; Salvatore Scianna; Igal Moaraf; Davide Schiavi; Claudia Scardino; Noé Corpataux; Julio Echarte-Morales; Michael Chrissoheris; Estefanía Fernández-Peregrina; Mattia Di Pasquale; Ander Regueiro; Carlos Vergara-Uzcategui; Andres Iñiguez-Romo; Felipe Fernández-Vázquez; Danny Dvir; Maurizio Taramasso; Mony Shuvy
Journal:  J Clin Med       Date:  2021-04-22       Impact factor: 4.241

6.  3D vena contracta area after MitraClip© procedure: precise quantification of residual mitral regurgitation and identification of prognostic information.

Authors:  Alexander Dietl; Christine Prieschenk; Franziska Eckert; Christoph Birner; Andreas Luchner; Lars S Maier; Stefan Buchner
Journal:  Cardiovasc Ultrasound       Date:  2018-01-09       Impact factor: 2.062

7.  A meta-analysis of MitraClip combined with medical therapy vs. medical therapy alone for treatment of mitral regurgitation in heart failure patients.

Authors:  Cristina Giannini; Fabrizio D'ascenzo; Francesca Fiorelli; Paolo Spontoni; Martin J Swaans; Eric J Velazquez; Patrizio Armeni; Marianna Adamo; Marco De Carlo; Anna Sonia Petronio
Journal:  ESC Heart Fail       Date:  2018-09-06

8.  Predictors of functional mitral regurgitation recurrence after percutaneous mitral valve repair.

Authors:  Katharina Hellhammer; Jean M Haurand; Maximilian Spieker; Peter Luedike; Tienush Rassaf; Tobias Zeus; Malte Kelm; Ralf Westenfeld; Patrick Horn
Journal:  Heart Vessels       Date:  2021-04-03       Impact factor: 2.037

9.  Predictors of functional improvement in the short term after MitraClip implantation in patients with secondary mitral regurgitation.

Authors:  Michael G Paulus; Christine Meindl; Lukas Böhm; Magdalena Holzapfel; Michael Hamerle; Christian Schach; Lars S Maier; Kurt Debl; Bernhard Unsöld; Christoph Birner
Journal:  PLoS One       Date:  2020-05-28       Impact factor: 3.240

Review 10.  Left ventricular restoration devices post myocardial infarction.

Authors:  Tom Hendriks; Remco A J Schurer; Lawien Al Ali; Ad F M van den Heuvel; Pim van der Harst
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.